Research Paper Volume 14, Issue 7 pp 3049—3069

Figure 5. CircGSE1 regulates the angiogenic ability of MAECs via the miR-323-5p. (A) Wound healing assay of OECs treated with vector, the miR-323-5p inhibitor or the miR-323-5p inhibitor + circGSE1 siRNA and YECs treated with the NC, miR-323-5p mimic or miR-323-5p mimic+OE-circGSE1. The graph indicates the quantification of the wounded area 24 hours after scratching (n=3, scale bar: 200 μm). (B) Tube formation assay of OECs treated with the vector, miR-323-5p inhibitor or miR-323-5p inhibitor+circGSE1 siRNA and YECs treated with the NC, miR-323-5p mimic or miR-323-5p mimic+OE-circGSE1 (n=3, scale bar, 200 μm). (C) Migration assay of OECs treated with the vector, miR-323-5p inhibitor or miR-323-5p inhibitor + circGSE1 siRNA and YECs treated with the NC, miR-323-5p mimic or miR-323-5p mimic+OE-circGSE1 (n=5, scale bar, 200 μm). (D) EdU assay of OECs treated with the vector, miR-323-5p inhibitor or miR-323-5p inhibitor + circGSE1 siRNA and YECs treated with the NC, miR-323-5p mimic or miR-323-5p mimic+OE-circGSE1 (n=5, scale bar, 200 μm). (The data are expressed as the mean ± SD, *P < 0.05 **P < 0.01 versus the negative control).